Drugs / Standard Dose Quadrivalent Inactivated Influenza Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05215327 | Nov 2022 → Jul 2027 expected | disease related to solid organ transplantation, influenza | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04613206 | Jan 2021 → Jul 2026 overdue | disease related to solid organ transplantation, influenza | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Standard Dose Quadrivalent Inactivated Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04613206 ↗ |
| Known as | Fluzone Quadrivalent | “Fluzone ® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by two influenza A subtype viruses and two type B viruses...” NCT04613206 ↗ |
| Modality | Vaccine | “is a vaccine indicated for active immunization” NCT04613206 ↗ |